Pro-Dex (NASDAQ:PDEX) Now Covered by StockNews.com

Stock analysts at StockNews.com initiated coverage on shares of Pro-Dex (NASDAQ:PDEX – Get Free Report) in a report released on Wednesday. The firm set a “buy” rating on the medical instruments supplier’s stock.

Pro-Dex Stock Performance

NASDAQ:PDEX opened at $18.65 on Wednesday. The company has a debt-to-equity ratio of 0.36, a current ratio of 3.07 and a quick ratio of 1.58. The firm has a market cap of $66.21 million, a PE ratio of 14.69 and a beta of 0.96. The firm has a 50 day simple moving average of $18.33 and a 200-day simple moving average of $17.12. Pro-Dex has a 1-year low of $14.47 and a 1-year high of $21.43.

Get Pro-Dex alerts:

Pro-Dex (NASDAQ:PDEX – Get Free Report) last released its quarterly earnings results on Thursday, May 4th. The medical instruments supplier reported $0.36 EPS for the quarter. The firm had revenue of $13.08 million for the quarter. Pro-Dex had a return on equity of 19.00% and a net margin of 9.72%.

Institutional Investors Weigh In On Pro-Dex

A number of hedge funds and other institutional investors have recently modified their holdings of the stock. Dimensional Fund Advisors LP lifted its holdings in shares of Pro-Dex by 1.1% in the fourth quarter. Dimensional Fund Advisors LP now owns 58,751 shares of the medical instruments supplier’s stock valued at $920,000 after purchasing an additional 625 shares in the last quarter. State Street Corp increased its position in Pro-Dex by 5.8% during the first quarter. State Street Corp now owns 11,923 shares of the medical instruments supplier’s stock worth $197,000 after acquiring an additional 650 shares during the period. Tower Research Capital LLC TRC grew its position in Pro-Dex by 345.6% in the 3rd quarter. Tower Research Capital LLC TRC now owns 2,687 shares of the medical instruments supplier’s stock worth $48,000 after purchasing an additional 2,084 shares during the last quarter. LSV Asset Management increased its stake in Pro-Dex by 13.9% during the first quarter. LSV Asset Management now owns 35,581 shares of the medical instruments supplier’s stock valued at $588,000 after acquiring an additional 4,346 shares during the period. Finally, UBS Group AG raised its stake in shares of Pro-Dex by 421.5% in the first quarter. UBS Group AG now owns 5,867 shares of the medical instruments supplier’s stock valued at $96,000 after purchasing an additional 4,742 shares in the last quarter. 14.61% of the stock is currently owned by institutional investors.

Pro-Dex Company Profile

(Get Free Report)

Pro-Dex, Inc designs, develops, manufactures, and sells powered surgical instruments for medical device original equipment manufacturers worldwide. The company offers autoclavable, battery-powered and electric, and multi-function surgical drivers and shavers that are primarily used in the orthopedic, thoracic, and craniomaxillofacial markets.

See Also

• Five stocks we like better than Pro-Dex
• Green Hydrogen Stocks Getting Ready to Deliver Big Gains
• Charles Schwab Gets The Rebound, Time to Buy?
• Is Ebix Inc a Phygital E-Commerce Contender or Pretender?
• 3 Mid-Cap Stocks with Expectations for High-Earnings Growth
• Can Lockheed Martin Fly To A New High In 2023?

Receive News & Ratings for Pro-Dex Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pro-Dex and related companies with MarketBeat.com's FREE daily email newsletter.